TheraRadar
Data updated: May 26, 2026

OFLOXACIN

Infectious Disease Approved 2002-01-16

OFLOXACIN is indicated for the treatment of Otitis Externa; Chronic Suppurative Otitis Media; Acute Otitis Media.

Source: FDA Label • Novartis
23
Indications
--
Phase 3 Trials
24
Years on Market

OFLOXACIN Approval History

2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
181 FDA actions from 2002 to 2026
Apr 2026 ORIGINAL
Update
Oct 2024 ORIGINAL
Update
Aug 2024 ORIGINAL
Update

What OFLOXACIN Treats

3 indications

OFLOXACIN is approved for 3 conditions since its original approval in 2002. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Otitis Externa
  • Chronic Suppurative Otitis Media
  • Acute Otitis Media
Source: FDA Label

OFLOXACIN Competitive Set

Pro

Three rings of competition based on shared molecular targets and treated indications.

Unlock 8 more competitors across all three rings.
Upgrade to Pro

Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.

Drugs Similar to OFLOXACIN

3 of 12

FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.

AUGMENTIN ES-600
AMOXICILLIN
1 shared
US ANTIBIOTICS
Shared indications:
AZITHROMYCIN
AZITHROMYCIN
1 shared
Sun Pharma
Shared indications:
BACTRIM
SULFAMETHOXAZOLE
1 shared
Sun Pharma
Shared indications:
📋

Clinical Trial Registry

5 trials
Trial Sponsor ID Phase Status Title
NCT03933631 PAACK 2018-9829 Ph 3 recruiting Pilocarpine Use After Kahook Goniotomy
NCT05302531 GRAAL 2021-001468-13 Ph 1 recruiting Absorption of Antibiotics With High Oral Bioavailability in Short-bowel Syndrome
NCT04005079 PACCT 2017-8704 Ph 3 withdrawn Pilocarpine After Combined Cataract/Trabectome Surgery
NCT04353362 Istanbul Medipol Ph 4 completed Alternative Antibiotic Regimen in Periodontitis Treatment
NCT01799356 Asicioglu03 treatment, treatment uPID Ph 4 completed Moxifloxacin Versus Ofloxacin Plus Metronidazole in Uncomplicated Pelvic Inflammatory Disease: Multicenter Randomized Controlled Trials
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

|
Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

OFLOXACIN FDA Label Details

Indications & Usage

FDA Label (PDF)

OFLOXACIN is indicated for the treatment of Otitis Externa; Chronic Suppurative Otitis Media; Acute Otitis Media.

Looking for the branded version?

OCUFLOX

Full clinical data, patents, trials, and competitive landscape for ofloxacin.

See OCUFLOX

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.